Lucid Diagnostics reports Q2 revenue of $1.5 million, adds coverage milestone
Lucid Diagnostics said second-quarter revenue rose about 17% from the prior quarter to $1.5 million as it performed 2,770 EsoGuard tests and secured its first laboratory benefit manager commercial coverage policy from Concert.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.